The 19th MedTech Investing Europe Conference

Transcription

1 The 19th MedTech Investing Europe Conference 23 & 24 September 2014 UIC-P Espaces Congrés, Paris, France Bringing Together Innovators, Leading Investors and Major Healthcare Corporations Organised by: Sponsored by: Host Sponsor:

2 Follow for the latest MTI updates and industry news. Use hashtag: #MTI14 About the event Now in its 19th edition The MedTech Investing Europe Conference sees Europe s longest established MedTech investment event coming to Paris for the first time. Offering a perfect combination of the latest investment opportunities and unrivalled programme content with insight and opinion from senior MedTech experts, this will be an unmissable event for those serious about MedTech investment. Pre-arranged one-to-one meetings and extensive networking opportunities will provide investors and entrepreneurs ample opportunity to identify and meet with the companies and individuals that are right for you. This year s agenda has been comprehensively researched and designed to cover the most up-to-date issues within this ever-developing sector and will provide delegates with the vital intelligence and advice needed to succeed in 2014 and beyond. Who should attend The delegate profile is made up of the following individuals: Investors with a core interest in MedTech Senior representatives from major healthcare corporations MedTech start-ups seeking financing Family offices and private investors MedTech specialists and service providers Previous participants by country and sector Attracting over 150 delegates who at the last event represented 22 countries, the MTI conference is THE meeting place for break-through technologies and leading MedTech investors. In % of the attendees purely focused on MedTech, with 28% investing in MedTech as part of a diverse investment portfolio. Government / Academia / Industry MedTech Presenting Company Media Partners: Consulting / Other MedTech Corporate VC / Private Equity / Other Private Investors Key statistics from MTI Lausanne Delegates 112 Companies 38 Presenting Companies show casing their technologies 24 Speakers 16 Countries represented 150+ Pre-booked one-to-one meetings Investor Advisory Board The Investor Advisory Board is made up of some of the most pro-active investors in the sector, with over 28bn AUM, they bring their wealth of experience and insight into the MTI series: Partner, Siemens Venture Capital, USA Investment Director, NBGI Ventures, UK Investment Director, Wellington Partners, Germany Investment Principal, Vinci Capital, Switzerland Managing Partner, Sofinnova Partners, France Director at BD Technologies, Becton Dickinson, USA Sr Managing Director, OrbiMed Healthcare Fund Management, Israel General Partner, 360 Capital Partners, Italy Partner, Abingworth, UK

3 Key benefits of attending Exclusive access to over 40 pioneering MedTech innovators who will showcase their latest innovations and provide investors with a diverse range of opportunities for investment. The presentations will be streamed for the benefit of the audience and will include product information, stage of business, expected growth rates, exit strategy plans and the level of funding required. Private one-to-one meetings with the innovators and investors of your choice to discuss potential business opportunities and foster future relationships. Last year over 150 meetings were booked prior to the event through our online networker, which will allow you to control your conference experience and make the most of your one-to-one meeting time by pre-arranging your twenty minute meetings with MedTech entrepreneurs and other industry leaders. You will also have the opportunity to access company profiles and be able to search by selecting the demographic of your choice. In-depth panel sessions and keynote presentations have been designed with industry experts to provide you with all the necessary information and guidance you need to flourish in today s economic climate. Key sessions include: State of the Nation Address How to succeed in MedTech Investment Strategies How are MedTech Investors adapting to provide funding today? Building a Successful MedTech Company The foundations of success Global Development Strategies Efficiently commercialising new technologies Digital Healthcare in Today s MedTech Environment How should MedTech adapt? Family Office & Private Wealth Investment The new sources of funding? A MedTech Success Story Building innovation into the DNA of your company Future of MedTech Investment The world s game-changers of tomorrow Great peer-to-peer networking opportunities with leading investors, major healthcare corporations and medical technology companies who will all be reunited under one roof, offering a chance to discuss new business opportunities. Innovators and technology providers looking for investment partnering include: GenetesiS S c i e n c e M a d e P e r s o n a l seiratherm Personalised Temperature Control TONGUE Lab These companies are just a sample of the ground-breaking investment opportunities available to investors at MTI Paris As soon as delegates complete registration all the Presenting Companies and their details will be made available.

4 08:30 09:15 Registration, refreshments and networking 09:15 09:30 Welcome from Paris Region CONFERENCE PROGRAMME DAY ONE Tuesday 23 September :30 09:40 Chairman s opening remarks Michel Darnaud President, International Business, Sorin Group, France 09:40 10:00 State of the Nation Address How to succeed in MedTech As changes, however gradual, are seen in the healthcare supply chain, primarily the interaction between clinicians and patients, the medical technology sector is having to adapt. Add to this an ever changing funding environment and it is essential all stakeholders clearly see what is affecting MedTech investment today. How can the sector as a whole continue to develop truly ground-breaking technologies? 10:00 11:00 Investment Strategies How are MedTech Investors adapting to provide funding today? Read the front cover of any newspaper and you will see a wealth of factors affecting the availability of funding and not just in the MedTech sector. Now more than ever there needs to be greater understanding and transparency between investors and technology companies to build tomorrow s success stories. So who is providing funding and how are investments being structured? How have investment amounts, timing and risk appetites changed for investors? What are the main beacons that attract an investor to an investment opportunity? Is globalisation a word synonymous with every investor s decision making? What realistic exit opportunities exist today and how important is it for founders to look this far ahead? Raphael Wisniewski Partner, Edmond de Rothschild Investment Partners, Switzerland Gadi Toren Venture Capital Investment Partner, Robert Bosch Venture Capital GmbH, Israel 11:00 11:20 Morning coffee and networking opportunity 11:20 12:20 Venues: Salle F List & Salle G Stephenson MedTech companies pitch their investment opportunities These sessions are dedicated to MedTech companies presenting innovative technology and investment opportunities in different sectors to an audience of investors. Each company will present for 10 minutes, in ONE of TWO Presentation Rooms.

5 12:20 13:20 Building a Successful MedTech Company The foundations of success There is no shortage of passionate and ambitious entrepreneurs generating ground-breaking concepts and research, but how can these ideas be translated into attractive companies for investors and onto successful businesses? The challenge is equally faced by the founders and the later investors so what makes a great idea and how should both groups work together to ensure success? What do investors look for and what involvement do investors have beyond funding? How should the board be structured and how can this be done with minimal conflict for founders and investors? What support is available to start-ups to help build into successful companies? Can European companies learn lessons from other regions on structural best practice? Daniel O Mahony, Partner, Seroba Kernel Life Sciences, Ireland John Power, CEO, Aerogen, Ireland Dr. Klaus Stöckemann, Managing Partner, Peppermint Venture Partners, Germany 13:20 14:30 Lunch and networking opportunity 14:30 15:40 Venues: Salle F List & Salle G Stephenson MedTech companies pitch their investment opportunities These sessions are dedicated to MedTech companies presenting innovative technology and investment opportunities in different sectors to an audience of investors. Each company will present for 10 minutes, in ONE of TWO Presentation Rooms. 15:40 16:40 Global Development Strategies Efficiently commercialising new technologies No longer should a MedTech company focus solely on their local market, global opportunities for commercialisation abound and there are undeniable profits to be made by looking further afield. Despite the world now being a smaller place, there are still radical differences in how regions/countries control their markets. So how do you decide where to place your tech and how do you gain market access? Are there parallels between regional/international markets and their regulation? Can you use experience, data and sales from one area to access others? Who covers the cost of global expansion? Do you need a corporate partner? How can investors and entrepreneurs overcome cultural differences? Janke Dittmer, Partner, Gilde Healthcare Partners, Netherlands Thomas Rasche, Partner, Earlybird Venture Capital, Germany 16:40 17:00 Afternoon coffee and networking opportunity 17:00 18:20 Venue: Dedicated Meeting Area ONE-2-ONE: Special pre-scheduled individual one-to-one meetings will be taking place in our dedicated meeting area. This session will consist of 4 x 20 minute one-to-one meetings. 18:20 19:30 Networking Drinks Reception Exclusively hosted by a sponsoring partner, this will be an informal reception allowing you to network with all attendees building and extending valuable networks.

6 CONFERENCE PROGRAMME DAY TWO Wednesday 24 September :30 09:30 Registration, breakfast refreshments and informal networking 09:30 09:40 Chairman s day two opening remarks Michel Darnaud President, International Business, Sorin Group, France 09:40 10:40 Digital Healthcare in Today s MedTech Environment How should MedTech adapt? Digital health has opened up new ways of delivering healthcare, more advanced patient/physician interaction and an evolving demand on technology capabilities. So what does this mean for the MedTech sector as a whole? Should digital health advancements be seen as a threat or a compliment to traditional medical technologies? From m-health to big data, how should digital health be defined? How do investment strategies in digital health technology vary from traditional MedTech? In what ways should device manufacturers incorporate digital health into their development? What are the limitations on digital health development and how is the sector regulated? Thierry Zylberberg Executive VP, Orange Healthcare, France Mounia Chaoui Associate Director, Turenne Santé, France 10:40 11:10 Family Office & Private Wealth Investment The new sources of funding? With investment cycles and appetites for risk changing in recent years, it is undeniable that investment focus has shifted from traditional sources. With this shift comes an opportunity for family offices and private wealth holders to step in and provide the funding for tomorrow s world-leading healthcare companies; but what are these investors looking for and what motivates them? Has the appetite of private investors changed in recent years? How much is the investment decision motivated by an emotional connection? What do investors bring to the companies in which they invest, beyond financial resources? Joanne Sawicki Director, Isocell Laboratories, UK Juan Carlos Castrosín Advisory Board Member, AAL Joint Partnership (AAL-JP), Belgium 11:10 11:30 A MedTech Success Story Building innovation into the DNA of your company Hear the first-hand experience of one of France s most successful consumer healthcare brands, how it has been built from an initial concept to turnover of over 200m and a clear vision of how it will continue to grow. Innovation comes in many forms and has been central to the company s success, from innovative technology to business models, hear the lessons learnt that can help your business. What is Laboratoires Urgo s view of innovation? How does Laboratoires Urgo approach R+D and new technology? Are there specific challenges faced by the company when accessing international markets and why is global expansion important to the business? Pierre Moustial CEO, Laboratoires Urgo, France

7 11:30 11:50 Morning coffee and networking opportunity 11:50 13:00 Venues: Salle F List & Salle G Stephenson MedTech companies pitch their investment opportunities These sessions are dedicated to MedTech companies presenting innovative technology and investment opportunities in different sectors to an audience of investors. Each company will present for 10 minutes, in ONE of TWO Presentation Rooms. 13:00 14:00 Lunch and networking opportunity 14:00 15:00 Future of MedTech Investment The world s game-changers of tomorrow In a constantly changing social, political and economic landscape there is one constant the demand for healthcare. How will entrepreneurs and investors have to adapt to successfully commercialise their technology in the coming years? What does the future of MedTech and the wider healthcare sector have in store and how can you position your companies to capitalise on future opportunities? What global trends are we going to see in the coming 24 months? How will regions and clusters support MedTech development in new ways? Who are the investors of tomorrow going to be? What factors affect the pipeline of start-ups who are exit ready? Bruno Montanari Life Sciences Director, Omnes Capital, France Antoine Papiernik Managing Partner, Sofinnova Partners, France Al Lauritano Director at BD Technologies, Becton Dickinson, USA 15:00 15:10 Chairman s Closing Remarks Michel Darnaud President, International Business, Sorin Group, France 15:10 16:50 Venue: Meeting Room ONE-2-ONE: Special pre-scheduled individual one-to-one meetings will be taking place in our dedicated meeting area. This session will consist of 5 x 20 minute one-to-one meetings. For delegates wishing to hold additional ad-hoc meetings, designated meeting space will be available at the venue beyond the official close of the conference. 16:50 End of conference Follow for the latest MTI updates and industry news. Use hashtag: #MTI14

8 The 19th MedTech Investing Europe Conference Ticket Options Early Bird Discount: 999 / 1233 (book by 31st July 2014) Standard Price: 1495 / 1845 Corporate Ticket 3 for the price of 2 : 2990 / 3690 Non-Qualifying Investor Ticket: 2000 / 2470 How to Register Visit and click on Book Now simidhillon@campdenwealth.com Call: +44 (0) /+44 (0) Interested in becoming a Presenting Company? Present your investment opportunity to an audience of private investors, venture capital and private equity partners and blue-chip corporations. For more information on Presenting Company opportunities please contact: Max Garry on +44 (0) , maxgarry@campdenwealth.com Gerald Schlagman on +44 (0) , geraldschlagman@campdenwealth.com Organised by: 140 London Wall, London, EC2Y 5DN, UK Tel: +44 (0) Fax: +44 (0) conferences@campdenwealth.com